A Phase II Pilot Study of Dovitinib (TKI258) in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Dovitinib (Primary)
- Indications Adenocarcinoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 04 Apr 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 02 Jun 2015 Status changed from active, no longer recruiting to completed, according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.